

Atara Biotherapeutics (ATRA : US\$28.05)

Atara Biotherapeutics soars 106.4% in trailing year, outperforming 97% of the market

Atara Biotherapeutics, Inc., soared US\$14.46 (or 106.4%) in the trailing 12 months to October 20, 2015 to close at US\$28.05. This means the stock has outperformed 97% of NASDAQ-listed stocks in the same period. Compared with the NASDAQ-100 Index which has risen 14.7% over the same period, this is a relative price increase of 91.7%.

Introduction with Trends

We are currently bearish on this stock in the long-term based on fundamental metrics, but are neutral in the short-term based on technical indicators

What makes us bearish on the stock is the following:

- The Price to Book of 7.8 higher than average of 7.0 for the Total Nasdaq Market and 7.0 for the Total NASDAQ Market.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 7.5. Compared with the rest of the market the stock is overvalued and ranks in the bottom 3% of stocks by value of Q Ratio.

However, there are some reasons why we remain neutral on the stock for the short-term:

- The stock is oversold according to the Williams % R indicator of -90.8.
- In the last three months the number of falls outnumbered rises 36:29 or 1.24:1.
- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.

Figure 1: Stock Identifiers

ISIN	US0465131078
PermID	1-5037937603
Central Index Key (CIK)	1604464
CUSIP	046513107

Fig 2: Stock Summary

Sector	Total Nasdaq Market
Market Cap	US\$799.8 million
Shares Outstanding	28,512,957
Relative Strength (3 mo)	4

Fig 3: Rank in American Region out of 11,894 stocks

Description	Value	Rank	Quartile
MCap (US\$)	799.8M	2,467	Top
Total Assets (US\$)	106.1M	5,412	Second
Net Profit (US\$)	(28M)	9,715	Bottom
Return on Equity %	(27.1)	6,572	Third
Price to Book	8.3	5,931	Second
PV\$1000 (1Year) US\$	2,202	265	Top
US\$ Change (1Year) %	120.2	256	Top
Rel Strength 6 Mo (US\$)	34	7,844	Third

Bullish Signals

- The stock is oversold according to the Williams % R indicator of -90.8.

Undervaluation:

- The company is cash rich with Cash to Market Capitalisation at 13.0%.

Other Bullish Signals:

Also, the following criteria set by Benjamin Graham:

- "Current ratio of two or more"; current assets are 38.9 times current liabilities.

Bearish Signals

- Falls to Rises: In the last three months the number of falls outnumbered rises 36:29 or 1.24:1.
- In the last 19 trading sessions there has been a net decline of 35.1%; the stock has retreated fourteen times and the biggest one day decline was 11.7% on Oct 08.
- In the NASDAQ market of 2,327 stocks and 1 unit traded today, the stock has a 6-month relative strength of 9 indicating it is trailing 91% of the market.
- Also, the relative strength percentile is slipping at 9 for 6 months, 4 for 3 months and 2 for 1 month.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 31.39 minus the 26-day EMA of 34.99 is negative suggesting a bearish signal. Both the 12-day EMA as well as the 26-day EMA are falling, another bearish signal.
- The Price/MAP 200 of 0.63 for Atara Biotherapeutics is lower than the Price/MAP 200 for the NASDAQ-100 Index of 1.0.
- The stock is trading below both its MAPs and the 50-day MAP of US\$39.94 is lower than the 200-day MAP of US\$44.80, a bearish indicator. The 200-day MAP has decreased to US\$44.80. A decrease is another bearish indicator.
- The price to 200-day MAP ratio is 0.63, a bearish indicator.
- The bears are maintaining control with price open, high, low and close being below yesterday's levels.

Overvaluation:

- The Price to Book of 7.8 higher than average of 7.0 for the Total Nasdaq Market and 7.0 for the Total NASDAQ Market.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 7.5. Compared with the rest of the market the stock is overvalued and ranks in the bottom 3% of stocks by value of Q Ratio.

Other Bearish Signals:

The stock has a score of merely 1 out of 9 set by Joseph Piotroski [pass mark ≥ 5]:

Improvement in current ratio from 34 to 38.9.

Fig 4: Bearish Indicators and Rank in Market

Description	Value	Rank In Market
Price to Book Value	7.8	In Bottom Quartile
Price/MAP200	0.63	In Bottom Quartile
Relative Strength (6M)	9	In Bottom 8%
Volatility %	10.3	In Bottom 8%
Price/MAP50	0.7	In Bottom 6%
Price Change %	-6.3	In Bottom 4%

Fig 5: Shareholder Returns

Trailing 12 Months: The stock rose 126 times (50% of the time), fell 122 times (48.4% of the time), was unchanged 3 times (1.2% of the time) and was untraded 1 time (0.4% of the time). The value of US\$1,000 invested a year ago is US\$2,064 [vs 1,147 for the NASDAQ-100 Index] for a capital gain of US\$1,064.

Fig 6: Recent Analyst Recommendations

Date	Brokerage	Action	Current Rating
25-Sep-2015	JMP Securities	Initiated Coverage	Market Perform
09-Sep-2015	Canaccord Genuity	Initiated Coverage	Buy

Price Volume Dynamics

Fig 7: Weekly Price Volume Dynamics (Last 12 Weeks)




Fig 8: Trailing 3 months

Turnover	US\$953.9 million
Volume	18,905,899
Volume Index (1 is avg)	1.9

Price Volume Dynamics

Fig 9: Trailing Price Change %

Price Change %	Quarter	Year	3 Years
ATRA	-50.18	106.4	
Total Nasdaq Market	-5.5	12.07	36.62
NASDAQ-100 index	-4	14.68	65.71

Fig 10: Turnover Rate & Turnover Period




Fig 11: Month-on-Month Comparison (Trailing Month - ended 20th)

	20 Oct	18 Sep	20 Aug	20 Jul	19 Jun	20 May
Price 20 Oct (USD)	28.05	48.97	42.8	56.3	54.13	39.45
% Price Change	-38.5	-1.1	-24	6.7	42.5	-26.4
Avg Daily Volume	203,065	182,552	169,147	159,341	127,890	110,674
VWP (USD)	42.04	51.42	52.72	50.32	45.91	40.65
Price Range (USD)	27.2 - 49.37	37.75 - 50.97	42.25 - 61.41	43.57 - 65.56	36.71 - 59.5	36 - 64.35
Relative Price Change %	-41.2	3.7	-17.7	3	42.3	-28.4
Volatility %	81.5	35	45.4	50.5	62.1	78.8

Price Volume Dynamics (continued)

Fig 12: Price Volume Trend: Trailing Quarter



Atara Biotherapeutics hit a 3-month high of US\$61 on Jul 28 and a 3-month low of US\$27 on Oct 15.

Ranking

Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

Ranking (continued)

Ranking

Atara Biotherapeutics, Inc. is placed 58/2204 in BSS ranking of NASDAQ performers in the past year, a percentile ranking of 97%.

Annual Report: Key Parameters

31 December, 2014

Annual Report: Atara Biotherapeutics reports Loss of USD28.0m

Atara Biotherapeutics (NASDAQ:ATRA) reported loss for the year-ended 31 December 2014 is USD28.0m.

Highlights

- Net tangible assets per share of USD20.7
- Loss USD28.0m
- EPS of -USD5.62
- Current ratio of 38.9
- Operating Cash Flow is negative
- Working capital to total assets of 97.3%

Annual

Company Name : Atara Biotherapeutics, Inc. (ATRA)

December 31 Description	2014 USD ('000)
Depreciation	6
Pre-Tax Profit/(Loss)	(28,031)
Profit/(Loss) after Tax	(28,006)
Working Capital	103,302
Current Assets	106,026
Current Liabilities	2,724
Shareholders' Funds	103,182
Total Liabilities	2,940
Total Assets	106,122
Cash and cash equivalents	21,897
Operating Cash Flow	(16,628)
Net Assets	103,182
Net Tangible Assets	103,182
Auditor	For Deloitte & Touche LLP

Per Share figures

December 31	2014
Cash	USD4.4
Working Capital	USD20.7
Shareholders' Funds	USD20.7
Total Liabilities	59c
Total Assets	USD21.3
Net Tangible Assets	USD20.7
EPS Final	(USD5.6)

December 31	2014
Performance Ratios	
Return on Equity (%)	(27.1)

Annual Report: Key Parameters (continued) 31 December, 2014

Return on Assets (%)	(26.4)
----------------------	--------

Current Ratio	38.9
---------------	------

Common Size Ratios by Assets %

Total current assets to Total Assets	99.9
--------------------------------------	------

Short-term investments to Total Assets	77.5
--	------

Cash to Total Assets	20.6
----------------------	------

Financial Results as reported (Annual)

31 December, 2014

Annual Report: Atara Biotherapeutics reports Income Before Tax of USD-28.0m

Atara Biotherapeutics (NASDAQ:ATRA) reported income before tax for the year-ended 31 December 2014 is USD-28.0m.

Financial statements as reported

(In USD Thousand, except per share data and shares outstanding)

Fig 13: Income Statement

Description	USD Thousand	USD Thousand	
Dec 31	2014	2013	Change %
Operating Expenses:			
Research and development	14,380	4,306	Up 234.0
Research and development costs paid to Amgen	1,066	553	Up 92.8
In-process research and development acquired from Amgen			
General and administrative	12,710	3,756	Up 238.4
Total operating expenses	28,156	8,615	Up 226.8
Loss from operations	-28,156	-8,615	Deterioration 226.8
Interest income	125	12	Up 941.7
Loss before provision for income taxes	-28,031	-8,603	Deterioration 225.8
Provision (benefit) for income taxes	25	170	Down 85.3
Net loss	-28,006	-8,773	Deterioration 219.2
Net loss per common share:			
Basic and diluted net loss per common share	-562.0c	-908.0c	Reduced 38.1
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	4,985,540	965,825	Up 416.2

Fig 14: Balance Sheet

Description	USD Thousand	USD Thousand	
Dec 31	2014	2013	Change %
Assets			
Current assets			
Cash and cash equivalents	21,897	51,615	Down 57.6
Short-term available-for-sale investments	82,219		
Prepaid expenses and other current assets	1,910	193	Up 889.6
Total current assets	106,026	51,808	Up 104.7
Property and equipment, net	48	8	Up 500.0
Other assets	48	12	Up 300.0
	96	20	Up 380.0
Total assets	106,122	51,828	Up 104.8

Financial Results as reported (Annual) (continued)

31 December, 2014

Liabilities, convertible preferred stock and stockholders' equity (deficit)			
Current liabilities:			
Accounts payable	440	606	Down 27.4
Accrued compensation	1,225	331	Up 270.1
Income tax payable	1	155	Down 99.4
Other accrued liabilities	1,058	432	Up 144.9
Total current liabilities	2,724	1,524	Up 78.7
Other long-term liabilities	216	230	Down 6.1
	216	230	Down 6.1
Total liabilities	2,940	1,754	Up 67.6
Commitments and contingencies			
Series A convertible preferred stock-0.0001 par value, liquidation preference of 20,088 as of December 31, 2013		109	
Series A-I convertible preferred stock-0.0001 par value, liquidation preference of 3,000 as of December 31, 2013		2,768	
Series B convertible preferred stock-0.0001 par value, liquidation preference of 52,000 as of December 31, 2013		38,414	
Stockholders' equity (deficit):			
Common stock-0.0001 par value, 19,692,937 and 12,003,891 shares 2 issued and outstanding as of December 31, 2014 and 2013, respectively		1	Up 100.0
Additional paid-in capital	144,169	2,200	Up 6,453.1
Notes receivable from stockholder		-335	
Accumulated other comprehensive loss	-100		
Accumulated deficit	-40,889	-12,883	Deterioration 217.4
Total stockholders' equity (deficit)	103,182	-11,017	Recovery
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	106,122	51,828	Up 104.8

Fig 15: Cash Flow

Description	USD Thousand	USD Thousand	
Dec 31	2014	2013	Change %
Operating activities			
Net loss	-28,006	-8,773	Deterioration 219.2
Adjustments to reconcile net loss to net cash used in operating activities:			
Non-cash research and development expenses	750		
In-process research and development acquired from Amgen			

Financial Results as reported (Annual) (continued)

31 December, 2014

Depreciation expense	6	4	Up 50.0
Investment premium amortization, net	526		
Stock-based compensation expense	10,101	1,713	Up 489.7
Interest accrued on notes receivable from stockholder	-2	-4	Improved 50.0
Changes in operating assets and liabilities:			
Other assets	-37	27	Deterioration
Prepaid expenses and other current assets	-1,246	-158	Deterioration 688.6
Accounts payable	-164	485	Deterioration
Income tax payable	-154	148	Deterioration
Other accrued liabilities	626	312	Up 100.6
Accrued compensation	894	280	Up 219.3
Other long-term liabilities	78		
Net cash used in operating activities	-16,628	-5,966	Deterioration 178.7
Investing activities			
Purchase of short-term investments	-95,525		
Maturities of short-term investments	12,208		
Purchase of property and equipment	-46	-3	Deterioration 1,433.3
Net cash used in investing activities	-83,363	-3	Deterioration 2,778,666.7
Financing activities			
Proceeds from sale of common stock, net of offering costs	56,455		
Repayment of notes receivable from stockholder	337		
Proceeds from sale of unvested restricted stock			
Proceeds from sale of convertible preferred stock	13,500	53,587	Down 74.8
Offering costs incurred in connection with sale of convertible preferred stock	-19	-210	Improved 91.0
Net cash provided by financing activities	70,273	53,377	Up 31.7
Increase (decrease) in cash and cash equivalents	-29,718	47,408	Deterioration
Cash and cash equivalents-beginning of period	51,615	4,207	Up 1,126.9
Cash and cash equivalents-end of period	21,897	51,615	Down 57.6
Non-cash financing activities			
Issuance of common stock for research and development expenses related to technology licensing option	750		
Issuance of Series A-I convertible preferred stock to Amgen in exchange for license		1,003	
Change in obligation to issue Series A-I convertible preferred stock to Amgen		-1,003	
Issuance of common stock upon vesting of stock awards	90	105	Down 14.3

Financial Results as reported (Annual) (continued)

31 December, 2014


Change in other long-term liabilities related to non-vested stock awards	-90	226	Deterioration
Restricted stock issued to related party in exchange for notes receivable		331	
Supplemental cash flow disclosure -Cash paid for taxes	70	22	Up 218.2

Institutional Holders Buying and Selling

Fig 16: List of Top 10 Institutional Holdings

Name of Shareholder	No. of Shares	% Held	Value USD
Baupost Group LLC,MA	4,763,265	19.55	133.6 M
Ecor1 Capital LLC	1,063,189	4.36	29.8 M
Visium Asset Management Lp	910,000	3.74	25.5 M
FMR LLC	693,833	2.85	19.5 M
Jennison Associates LLC	594,758	2.44	16.7 M
Bridger Management LLC	474,835	1.95	13.3 M
Neuberger Berman Group LLC	446,777	1.83	12.5 M
Redmile Group LLC	265,205	1.09	7.4 M
Everpoint Asset Management LLC	252,349	1.04	7.1 M
Vanguard Group Inc	216,488	0.89	6.1 M
Total	9,680,699	39.74	

Fig 17: Top 20 Institutional Holdings as % of total



Institutional Shareholders Summary

The following transactions were reported to the SEC for the quarter ended 30 June 2015 by institutions holding more than \$100m of total investments.

30 June 2015 share price of Atara Biotherapeutics: US\$52.76

19 Institutions bought 504,820 shares valued at US\$26.6 million.

3 Institutions sold 131,383 shares valued at US\$6.9 million.

Net reported buying by 22 institutions in the quarter: US\$19.7 million.

Institutional Shareholders Buying

Top 9 Holders

Baupost Group LLC,MA buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Baupost Group LLC,MA bought 46,367 shares in the quarter ended Jun 30, 2015. Baupost Group LLC,MA now holds 4,809,632 shares or 0.22% worth USD192.5 million.

Ecor1 Capital, LLC buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Ecor1 Capital, LLC bought 62,811 shares in the quarter ended Jun 30, 2015. Ecor1 Capital, LLC now holds 1,063,189 shares worth USD45.5 million.

Blackrock Fund Advisors buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Blackrock Fund Advisors bought 152,477 shares in the quarter ended Jun 30, 2015. Blackrock Fund Advisors now holds 346,203 shares worth USD14.8 million.

Blackrock Institutional Trust Company, N.A. buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Blackrock Institutional Trust Company, N.A. bought 110,822 shares in the quarter ended Jun 30, 2015. Blackrock Institutional Trust Company, N.A. now holds 183,679 shares worth USD7.7 million.

Institutional Holders Buying and Selling (continued)

Arrowpoint Asset Management, LLC buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Arrowpoint Asset Management, LLC bought 1,534 shares in the quarter ended Jun 30, 2015. Arrowpoint Asset Management, LLC now holds 123,668 shares worth USD5.2 million.

Tiaa Cref Investment Management LLC buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Tiaa Cref Investment Management LLC bought 46,124 shares in the quarter ended Jun 30, 2015. Tiaa Cref Investment Management LLC now holds 65,245 shares worth USD2.7 million.

Blackrock Investment Management, LLC buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Blackrock Investment Management, LLC bought 28,507 shares in the quarter ended Jun 30, 2015. Blackrock Investment Management, LLC now holds 48,860 shares worth USD2.1 million.

Schwab Charles Investment Management Inc buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Schwab Charles Investment Management Inc bought 9,781 shares in the quarter ended Jun 30, 2015. Schwab Charles Investment Management Inc now holds 30,796 shares worth USD1.3 million.

American International Group Inc buys

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder American International Group Inc bought 4,877 shares in the quarter ended Jun 30, 2015. American International Group Inc now holds 8,492 shares or 0.39% worth USD339,850.

Institutional Shareholders Selling

Top 2 Holders

Visium Asset Management, LP sells

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Visium Asset Management, LP sold 16,782 shares in the quarter ended Jun 30, 2015. Visium Asset Management, LP now holds 887,268 shares worth USD38 million.

Neuberger Berman Group LLC sells

Atara Biotherapeutics (NASDAQ:ATRA) institutional shareholder Neuberger Berman Group LLC sold 757 shares in the quarter ended Jun 30, 2015. Neuberger Berman Group LLC now holds 446,020 shares worth USD19.1 million.

Company Overview and Regulatory Announcements

Activities

Atara Biotherapeutics, Inc a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The Company's product candidates are biologics targeting myostatin and activin, members of the Transforming Growth Factor-Beta, or TGF- β , protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues.

Further details can be found at <http://www.atarabio.com>.

Issued Capital

Based on 28,512,957 issued equity shares the market capitalisation is US\$799.8 million.

The top twenty shareholders hold 44.7% of the issued capital leaving a float of 55.3%.

Fig 18: Reported Selling

Name	Date	Transaction Type	No. of Shares	Price, USD	Value, USD
Ciechanover Isaac E.	Oct 06, 2015	Sold	2,000	31.38	62,753
Ciechanover Isaac E.	Oct 07, 2015	Sold	2,000	34.79	69,583
Ciechanover Isaac E.	Sep 23, 2015	Sold	2,600	43.29	112,554
Ciechanover Isaac E.	Sep 24, 2015	Sold	2,600	42.68	110,977
Ciechanover Isaac E.	Sep 10, 2015	Sold	2,600	45.89	119,324
Ciechanover Isaac E.	Sep 11, 2015	Sold	2,600	46.43	120,721

Fig 19: Reported Trades



8-K people news

June 29: Atara Biotherapeutics Elects 3 Directors

Atara Biotherapeutics (ATRA) held its Annual General Meeting on June 25, 2015. According to an SEC filing under Section 8-K Item 5.07 the following directors were elected:

Eric L. Dobmeier
Beth Seidenberg
Eckard Weber

8-K other news

September 14: Atara Biotherapeutics: Entry into a Material Definitive Agreement

[News Story] Source: SEC

August 06: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459015006337_0001564590-15-006337.txt

Source: Securities and Exchange Commission

June 15: Atara Biotherapeutics: Entry into a Material Definitive Agreement

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000119312515223458_0001193125-15-223458.txt

Source: Securities and Exchange Commission

Regulatory Announcements (continued)

May 07: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459015003599_0001564590-15-003599.txt

Source: Securities and Exchange Commission

February 26: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459015001022_0001564590-15-001022.txt

Source: Securities and Exchange Commission

November 12: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459014005468_0001564590-14-005468.txt

Source: Securities and Exchange Commission

Meetings

June 23: Atara Biotherapeutics announces AGM

Atara Biotherapeutics has announced its Annual General Meeting will take place on 25 June 2015.

Changes in Board and Management

March 27: Atara Biotherapeutics appoints Director

Atara Biotherapeutics has appointed Eric Dobmeier as a Director. The effective date is March 27, 2015.

Performance

August 06: Atara Biotherapeutics Announces Second Quarter 2015 Results

[News Story] SOUTH SAN FRANCISCO, Calif., Aug. 6, 2015

(GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc.

(Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the second quarter ended June 30, 2015.

Second Quarter 2015 Strategic and Operational Highlights

Second Quarter 2015 Financial Results

[Read more...](http://www.nasdaq.com/press-release/atara-biotherapeutics-announces-second-quarter-2015-results-20150806-00167)

Source: Nasdaq Stock Exchange

[For more details click here.](#)

May 07: Atara Biotherapeutics Announces First Quarter 2015 Results

[News Story] SOUTH SAN FRANCISCO, Calif., May 7, 2015

(GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc.

(Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the first quarter ended March 31, 2015.

[For more details click here.](#)

February 27: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results

[News Story] SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 --

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a

biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the fourth quarter and full year ended December 31, 2014.

[For more details click here.](#)

November 12 2014: Atara Biotherapeutics Announces Third Quarter 2014 Operating Results

[News Story]

<http://www.nasdaq.com/aspx/stockmarketnewsstoryprint.aspx?storyid=atara-biotherapeutics-announces-third-quarter-2014-operating-results-20141112-00188>

Source: Nasdaq Stock Exchange

[For more details click here.](#)

Press Releases

October 20: Atara Bio Receives Fda Orphan Drug Designation For Stm 434, Atara Bio's Activin Inhibitor For Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2015 (GLOBE

NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a

biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that the U.S.

[For more details click here.](#)

October 20: Atara Bio Receives Fda Orphan Drug Designation For Stm 434, Atara Bio's Activin Inhibitor For Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2015 (GLOBE

NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a

biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that the U.S.

[For more details click here.](#)

Regulatory Announcements (continued)

October 14: Atara Bio To Host Investor Day On October 21, 2015

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc., (Nasdaq:ATRA), today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, October 21, 2015 at 12:00p.m. ET in New York, NY.

The live audio webcast and the accompanying slide presentations can be accessed through the Events & Presentations section of the Company's website at investors.atarabio.com.

[For more details click here.](#)

October 05: Atara Bio's Collaborating Investigators To Present Data At The American Society Of Nephrology Kidney Week 2015

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Baylor College of Medicine will present at the American Society of Nephrology (ASN) Kidney Week 2015.

[For more details click here.](#)

October 05: Atara Bio's Pinta 745 Improves Insulin Sensitivity And Alters Fat Metabolism In Mice Fed With A High Fat Diet

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the publication of preclinical data that provide insight into the pharmacology of its clinical stage anti-myostatin peptibody, PINTA 745.

In the International Journal of Obesity, investigators from Baylor College of Medicine utilized a high fat diet (HFD)-fed mouse model of obesity and type II diabetes to evaluate the effects of myostatin inhibition using PINTA 745.

The paper is available at the following web location:

<http://www.nature.com/ijo/journal/vaop/naam/index.html#05102015>

Source: Nasdaq Stock Exchange

[For more details click here.](#)

September 24: Atara Bio's T-cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results In Patients With Plasma Cell Leukemia

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented clinical data on cytotoxic T lymphocytes (CTL) activated against Wilms' Tumor 1 (WT1-CTL) at the 15th International Myeloma Workshop in Rome, Italy.

[For more details click here.](#)

September 02: Atara Biotherapeutics, Inc. To Present At Upcoming Investor Conferences In September 2015

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will present at the investor conferences listed below.

The live audio webcast of the Company presentation from the Morgan Stanley Global Healthcare Conference will be accessible from the Company's investor relations website at <http://investors.atarabio.com/events.cfm>.

[For more details click here.](#)

August 31: Atara Biotherapeutics Announces Completion Of Enrollment In Pinta 745 Phase 2 Clinical Trial In End-stage Renal Disease Patients With Protein Energy Wasting

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it completed enrollment in its blinded, randomized, PINTA 745 Phase 2 clinical trial in End-Stage Renal Disease (ESRD) patients with Protein Energy Wasting (PEW).

[For more details click here.](#)

August 19: Atara Biotherapeutics director exercises Restricted Stock Units and buys shares

Atara Biotherapeutics director Fust Matthew K, exercised Restricted Stock Units and purchased 1,603 shares worth approximately US\$80,246 on August 17, 2015.

[For more details click here.](#)

August 19: Atara Biotherapeutics director exercises Restricted Stock Units and buys shares

Atara Biotherapeutics director Ciechanover Isaac E., exercised Restricted Stock Units and purchased 5,907 shares worth approximately US\$295,704 on August 17, 2015.

[For more details click here.](#)

Regulatory Announcements (continued)

July 15: Atara Bio Announces Closing Of Underwritten Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

[News Story] SOUTH SAN FRANCISCO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the closing of its underwritten public offering of 3,980,768 shares of its common stock at a public offering price of \$52.00 per share, which included 519,230 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares.

[For more details click here.](#)

July 09: Atara Bio Announces Pricing Of Its \$180.0 Million Offering Of Common Stock

[News Story] SOUTH SAN FRANCISCO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of 3,461,538 shares of its common stock at a public offering price of \$52.00 per share.

[For more details click here.](#)

July 07: Atara Bio Announces Proposed Offering Of Common Stock

[News Story] SOUTH SAN FRANCISCO, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately \$125.0 million.

[For more details click here.](#)

June 29: Atara Biotherapeutics: Submission of Matters to a Vote of Security Holders

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459015005294_0001564590-15-005294.txt

Source: Securities and Exchange Commission

June 15: Atara Biotherapeutics Exercises Exclusive License To T-cell Technology From Memorial Sloan Kettering Cancer Center

[News Story] SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it has exercised its exclusive option with Memorial Sloan Kettering Cancer Center (MSK) to license certain clinical stage, allogeneic T-cell therapies for the treatment of cancers and persistent viral infections.

[For more details click here.](#)

May 27: Atara Biotherapeutics, Inc. To Present At Upcoming Investor Conferences In June 2015

[News Story] SOUTH SAN FRANCISCO, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will webcast its presentations at the below listed investor conferences in June 2015.

The live audio webcasts of the company presentations will be accessible from the company's investor relations website at <http://investors.atarabio.com/events.cfm>.

[For more details click here.](#)

May 20: Update: Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

[News Story] SOUTH SAN FRANCISCO, Calif., May 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the American Society of Clinical Oncology 2015 Annual Meeting website was updated for abstract 10016 being presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK).

[For more details click here.](#)

May 14: Atara Biotherapeutics: Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

[News Story] SOUTH SAN FRANCISCO, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at the 2015 American Society of Clinical Oncology Annual Meeting (ASCO).

[For more details click here.](#)

May 12: Events Calendar: Atara Biotherapeutics, Inc. to Present at the UBS Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 12, 2015 Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, the company's President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 4:00 pm EDT in New York City.

The live audio webcast of the company presentation will be accessible from the company's investor relations website at <http://investors.atarabio.com/events.cfm>.

[For more details click here.](#)

Regulatory Announcements (continued)

April 22: EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

[News Story] SOUTH SAN FRANCISCO, Calif., April 20, 2015 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the 2015 American Association for Cancer Research Annual Meeting (AACR).

[For more details click here.](#)

April 19: Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available

[News Story] SOUTH SAN FRANCISCO, Calif., April 19, 2015 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) that will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015 is now available.

[For more details click here.](#)

April 13: Atara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit

SOUTH SAN FRANCISCO, Calif., April 13, 2015 Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at 11:00 am EDT in Boston.

Source: Nasdaq Stock Exchange

[For more details click here.](#)

April 10: Events Calendar: Atara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference

[News Story] SOUTH SAN FRANCISCO, Calif., April 9, 2015 Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New York City. The live audio webcast of the company presentation will be accessible from the company's investor relations website at <http://investors.atarabio.com/events.cfm>.

[For more details click here.](#)

March 30: Atara Biotherapeutics director awarded Non-qualified stock options

Atara Biotherapeutics (NASDAQ:ATRA) director Dobmeier Eric, has been awarded Non-qualified stock options on 25,000 shares at an exercise price of US\$34.90. The transaction date was March 26, 2015. The shares last traded at US\$42.90.

March 19: Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015

[News Story] Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015.

[For more details click here.](#)

March 03: Atara Biotherapeutics Names David A. Carmel as Head of Immunotherapy

[News Story] SOUTH SAN FRANCISCO, Calif., THOUSAND OAKS, Calif., and NEW YORK, March 3, 2015 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on innovative therapies for patients with debilitating diseases, announced today that it has hired David A. Carmel as Head of Immunotherapy.

[For more details click here.](#)

February 19: Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares

[News Story] SOUTH SAN FRANCISCO, Calif., Feb. 18, 2015 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the closing of its public offering of 4,147,358 shares of its common stock at a public offering price of \$18.00 per share, which included 509,025 shares sold pursuant to the partial exercise by the underwriters of their option to purchase additional shares.

[For more details click here.](#)

February 12: Atara Bio Announces Pricing of Its \$65.5 Million Offering of Common Stock

[News Story] SOUTH SAN FRANCISCO, Calif., Feb. 12, 2015 - Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of 3,638,333 shares of its common stock at a public offering price of \$18.00 per share.

[For more details click here.](#)

February 09: Atara Bio Announces Proposed Offering of Common Stock

[News Story] SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 - Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock.

[For more details click here.](#)

Regulatory Announcements (continued)

January 21: Atara Biotherapeutics Director awarded Non-qualified stock options

Atara Biotherapeutics (NASDAQ:ATRA) Director Gallagher Carol Giltner, has been awarded Non-qualified stock options on 12,500 shares at an exercise price of US\$25.15. The transaction date was January 16, 2015. The shares last traded at US\$23.45.

January 21: Atara Biotherapeutics Director awarded Non-qualified stock options

Atara Biotherapeutics (NASDAQ:ATRA) Director Fust Matthew K, has been awarded Non-qualified stock options on 12,500 shares at an exercise price of US\$25.15. The transaction date was January 16, 2015. The shares last traded at US\$23.45.

January 21: Atara Biotherapeutics Director awarded Employee Stock Options

Atara Biotherapeutics (NASDAQ:ATRA) Director Ciechanover Isaac E., has been awarded Employee Stock Options on 126,667 shares at an exercise price of US\$25.15. The transaction date was January 16, 2015. The shares last traded at US\$23.45.

January 21: Atara Biotherapeutics Director awarded shares

Atara Biotherapeutics (NASDAQ:ATRA) Director Ciechanover Isaac E., was awarded 38,000 shares worth US\$950,380 on January 16, 2015.

January 09: Atara to Present at the J.P. Morgan Healthcare Conference

[News Story] SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 J.P.

[For more details click here.](#)

November 06 2014: Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014

[News Story] BRISBANE, Calif., Nov. 6, 2014 Atara

Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present at the Annual Meeting of the American Society of Hematology (ASH) 2014.

[For more details click here.](#)

Board and Management & creation of shareholder value



Isaac Ciechanover
CEO & President & Director

Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in August 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene's Executive Director for Business Development, he spearheaded the company's venture capital efforts and led licensing and M&A activities with an aggregate value of more than \$6.7 billion. Also at Celgene, he was Global Project Leader for the company's first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures' healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd's "The Dark Side of the Moon," Radiohead's "OK Computer" and Ruggero Leoncavallo's Italian opera, Pagliacci, with Herbert Von Karajan conducting.

Carol Gallagher Executive Chairman & Director

Dr. Carol Gallagher serves as the Lead Independent Director of Atara Biotherapeutics. She recently joined the life sciences practice of New Enterprise Associates as a Partner. She serves as Chairman of AnaptysBio and as a Director at Atterocor. From 2008-2011, Carol was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Carol raised \$80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for \$375 million and a total consideration of \$600 million. Gilead continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously. Carol studied chemistry at Vanderbilt University and then pursued a clinical background, attaining Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.

John F. McGrath CFO

John F. McGrath, Jr. joined Atara Biotherapeutics as Chief Financial Officer in January 2013. He was previously Executive in Residence and Operating Partner at Kleiner Perkins Caufield & Byers. John was also Vice President and Chief Financial Officer for Network Equipment Technologies, Inc., which developed and sold network equipment for real-time communications. Earlier in his career, he was Vice President of Finance for Aspect Communications, Director of Finance for TCSI Corporation and Manager in the High Technology and Manufacturing practice at Ernst & Young. John is a registered C.P.A. (inactive) in California and earned a B.S. from the University of Wyoming and an M.B.A. from the Stanford Graduate School of Business. John has served on the board of the Presidio Fund, a publicly traded mutual fund, and as Audit Committee Chairman on the boards of Actel Corporation and Endwave Corporation. Away from work, John enjoys running (including three marathons), swimming and traveling.

Eric Dobmeier Director

Mr. Dobmeier is currently the Chief Operating Officer of Seattle Genetics, Inc., a biotechnology company. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then, most recently as Chief Business Officer from May 2007 to June 2011. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier also serves as a director of Stemline Therapeutics, Inc., a public biotechnology company. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University.

Creation of shareholder value in Atara Biotherapeutics: Since appointment as Director: The present value of USD1,000 invested on the appointment date of March 27, 2015 at close price of US\$36.77 is US\$763, for a capital loss of US\$237.

Matthew Fust Director

Matthew Fust was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals from January 2009 through the acquisition of the company in October 2013. From May 2003 to December 2008, Matthew served as Chief Financial Officer of Jazz Pharmaceuticals. From 2002 to 2003, he served as Chief Financial Officer of Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Matthew was a member of Andersen Consulting's healthcare strategy practice. He received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business. Matthew is a director of MacroGenics, Sunesis Pharmaceuticals, and Ultragenyx Pharmaceutical.

Board and Management & creation of shareholder value (continued)

Christopher Haqq Chief Medical Officer

Dr. Christopher Haqq joined Atara Biotherapeutics as Chief Medical Officer in September 2012. He brings 20 years of clinical, academic and drug development experience from biopharma companies large and small. He was recently Vice President for Clinical Research and Development at Cougar Biotechnology and Johnson & Johnson's Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Previously at Amgen, he led early development studies of the anti-insulin like growth factor type 1 receptor AMG 479 (ganitumab) antibody. He has served as medical monitor for more than 10 clinical trials and has contributed to drug development programs for a wide range of molecules. Chris has worked closely with the European Medicines Agency, the U.S. Food and Drug Administration and other global regulatory agencies filing IND applications, new drug applications, special protocol assessments and their international equivalents. Earlier in his career, Chris practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. In his post-graduate training, also at UCSF, he served as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Chris completed his M.D. and Ph.D. at Harvard Medical School and his B.S. at Stanford University. He is board certified in Medical Oncology and Internal Medicine. Chris is an inventor of three patents and an author of nearly 50 medical publications. In his free time, he enjoys astronomy and photography.

Glossary

Capital Gain/Loss from n Years Ago to n-1 Years Ago:

Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)

Current Ratio:

Current Assets/Current Liabilities (times)

Price Close/Moving Avg Price (Fig 4):

Latest Price/Moving Average Price

Relative Price Change (Fig 11):

Today's Relative price change with respect to Benchmark Index

Return on Assets:

Net Profit/Total Assets (%)

Turnover (Fig 8):

Last Price * Volume

Turnover Rate (Fig 10):

US Dollar value of annual trading volume as a percentage of market capitalisation

Volume Index (VI) (Fig 8):

Number of shares traded in the period/Average number of shares traded for the period

Cash/MCap:

Cash plus Liquids/Market Capitalisation (times)

Moving Average Price (n periods) (Fig 4):

Sum of Prices for each Period/Number of Periods

Price/NTA (Fig 3, 4):

Closing Share Price/Net Tangible Assets Per Share (times)

Relative Strength (n-th Period) (Fig 2, 4, 3):

Price close today/Price close 'n' periods ago, then ranked by percentile within the entire market.

Return on Equity (Shareholders' Funds) (Fig 3):

Net Profit/Net Assets (%)

Turnover Period (Fig 10):

Time Period required for trading all Outstanding Shares

Volatility (Fig 4, 11):

Highest Price minus Lowest Price/Lowest Price (%)

Volume Weighted Price (VWP) (Fig 11):

The Volume Weighted Price (VWP) is the summation of turnover divided by total volume in the same period.

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

For further details on definitions and quotations from investing legends, [Click here](#)

For any enquiries, please email: feedback@buysellsignals.com

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756), who provide round the clock data on every stock and sector. BuySellSignals is not a broker, and does not have an executing, corporate advisory or investment banking function. BuySellSignals, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.